Literature DB >> 27757000

Mepolizumab (Nucala) For Severe Eosinophilic Asthma.

Min Sung Choy, Deepali Dixit, Mary Barna Bridgeman.   

Abstract

Mepolizumab (Nucala) for severe eosinophilic asthma.

Entities:  

Year:  2016        PMID： 27757000      PMCID： PMC5046999     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  13 in total

1.  Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis.

Authors:  Pranabashis Haldar; Christopher E Brightling; Amisha Singapuri; Beverley Hargadon; Sumit Gupta; William Monteiro; Peter Bradding; Ruth H Green; Andrew J Wardlaw; Hector Ortega; Ian D Pavord
Journal:  J Allergy Clin Immunol       Date:  2014-01-10       Impact factor: 10.793

Review 2.  Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody.

Authors:  Deborah A Smith; Elisabeth A Minthorn; Misba Beerahee
Journal:  Clin Pharmacokinet       Date:  2011-04       Impact factor: 6.447

3.  Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response.

Authors:  M J Leckie; A ten Brinke; J Khan; Z Diamant; B J O'Connor; C M Walls; A K Mathur; H C Cowley; K F Chung; R Djukanovic; T T Hansel; S T Holgate; P J Sterk; P J Barnes
Journal:  Lancet       Date:  2000 Dec 23-30       Impact factor: 79.321

4.  Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.

Authors:  W Busse; J Corren; B Q Lanier; M McAlary; A Fowler-Taylor; G D Cioppa; A van As; N Gupta
Journal:  J Allergy Clin Immunol       Date:  2001-08       Impact factor: 10.793

5.  Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

Authors:  M Humbert; R Beasley; J Ayres; R Slavin; J Hébert; J Bousquet; K-M Beeh; S Ramos; G W Canonica; S Hedgecock; H Fox; M Blogg; K Surrey
Journal:  Allergy       Date:  2005-03       Impact factor: 13.146

6.  Strategy aimed at reduction of sputum eosinophils decreases exacerbation rate in patients with asthma.

Authors:  J Chlumský; I Striz; M Terl; J Vondracek
Journal:  J Int Med Res       Date:  2006 Mar-Apr       Impact factor: 1.671

7.  International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma.

Authors:  Kian Fan Chung; Sally E Wenzel; Jan L Brozek; Andrew Bush; Mario Castro; Peter J Sterk; Ian M Adcock; Eric D Bateman; Elisabeth H Bel; Eugene R Bleecker; Louis-Philippe Boulet; Christopher Brightling; Pascal Chanez; Sven-Erik Dahlen; Ratko Djukanovic; Urs Frey; Mina Gaga; Peter Gibson; Qutayba Hamid; Nizar N Jajour; Thais Mauad; Ronald L Sorkness; W Gerald Teague
Journal:  Eur Respir J       Date:  2013-12-12       Impact factor: 16.671

8.  Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment.

Authors:  A Magnan; A Bourdin; C M Prazma; F C Albers; R G Price; S W Yancey; H Ortega
Journal:  Allergy       Date:  2016-05-24       Impact factor: 13.146

9.  Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.

Authors:  Elisabeth H Bel; Sally E Wenzel; Philip J Thompson; Charlene M Prazma; Oliver N Keene; Steven W Yancey; Hector G Ortega; Ian D Pavord
Journal:  N Engl J Med       Date:  2014-09-08       Impact factor: 91.245

10.  Mepolizumab treatment in patients with severe eosinophilic asthma.

Authors:  Hector G Ortega; Mark C Liu; Ian D Pavord; Guy G Brusselle; J Mark FitzGerald; Alfredo Chetta; Marc Humbert; Lynn E Katz; Oliver N Keene; Steven W Yancey; Pascal Chanez
Journal:  N Engl J Med       Date:  2014-09-08       Impact factor: 91.245
View more
  2 in total

1.  Mepolizumab does not prevent all aspirin-induced reactions in patients with aspirin-exacerbated respiratory disease: A case series.

Authors:  Hannah Martin; Nora Amanda Barrett; Tanya Laidlaw
Journal:  J Allergy Clin Immunol Pract       Date:  2020-09-19

Review 2.  Treating severe asthma: Targeting the IL-5 pathway.

Authors:  Stefania Principe; Celeste Porsbjerg; Sisse Bolm Ditlev; Ditte Kjaersgaard Klein; Korneliusz Golebski; Nanna Dyhre-Petersen; Yoni E van Dijk; Job J M H van Bragt; Lente L H Dankelman; Sven-Erik Dahlen; Christopher E Brightling; Susanne J H Vijverberg; Anke H Maitland-van der Zee
Journal:  Clin Exp Allergy       Date:  2021-05-21       Impact factor: 5.018
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.